Printer Friendly

BRISTOL-MYERS SQUIBB FILES NDA WITH FDA TO MARKET TAXOL

 BRISTOL-MYERS SQUIBB FILES NDA WITH FDA TO MARKET TAXOL
 NEW YORK, July 31 /PRNewswire/ -- Bristol-Myers Squibb Company


(NYSE: BMY) today announced that it has filed a new drug application (NDA) with the United States Food and Drug Administration (FDA) seeking approval to market the anti-cancer drug Taxol(R). The NDA was filed on July 22.
 In announcing the NDA filing, the company said that it is voluntarily relinquishing "orphan drug" status previously granted to Taxol.
 -0- 7/31/92
 /CONTACT: Jon Weisberg of Bristol-Myers Squibb, 212-546-4343/
 (BMY) CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU:


TS -- NY025 -- 5526 07/31/92 10:47 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 31, 1992
Words:106
Previous Article:PHELPS DODGE CORPORATION DECLARES THIRD QUARTER DIVIDEND
Next Article:BOONE PICKENS, ASA JOHAL, SIDNEY TASSIN TO JOIN LESSONWARE TEAM
Topics:


Related Articles
BRISTOL-MYERS SQUIBB ACCELERATES PRODUCTION OF ANTI-CANCER DRUG, TAXOL
BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON TAXOL
FDA ADVISORY COMMITTEE MAKES RECOMMENDATION FOR APPROVAL OF BRISTOL-MYERS SQUIBB COMPANY'S ANTIDEPRESSANT DRUG
BRISTOL-MYERS SQUIBB FILES NEW DRUG APPLICATION FOR ANTI-AIDS DRUG ZERIT (STAVUDINE, d4T)
FDA CLEARS TAXOL(R) (PACLITAXEL) FOR USE IN TREATMENT OF METASTATIC BREAST CANCER AFTER FIRST-LINE THERAPY FAILS
PACLITAXEL CLINICAL TRIALS INITIATED IN THE UNITED STATES
FDA CLEARS ANTICANCER DRUG TAXOL (PACLITAXEL), PRODUCED SEMISYNTHETICALLY FROM RENEWABLE SOURCES
BRISTOL-MYERS SQUIBB ANNOUNCES SUPPORT FOR THREE MAJOR CLINICAL STUDIES OF TAXOL(R) (paclitaxel) IN BREAST CANCER
Bristol-Myers Squibb Announces Agreements with The National Institutes of Health
IVAX Announces FDA Advisory Panel to Review Paxene(R) for Kaposi's Sarcoma

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters